Cargando…

Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer

Blood methylated cell-free DNA (cfDNA) as a minimally invasive cancer biomarker has great importance in cancer management. Guanylate binding protein 2 (GBP2) has been considered as a possible controlling factor in tumor development. GBP2 gene expression and its promoter methylation status in both pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahvar, Farzaneh, Salimi, Mahdieh, Mozdarani, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Genética 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783727/
https://www.ncbi.nlm.nih.gov/pubmed/33211060
http://dx.doi.org/10.1590/1678-4685-GMB-2019-0230
_version_ 1783632167662780416
author Rahvar, Farzaneh
Salimi, Mahdieh
Mozdarani, Hossein
author_facet Rahvar, Farzaneh
Salimi, Mahdieh
Mozdarani, Hossein
author_sort Rahvar, Farzaneh
collection PubMed
description Blood methylated cell-free DNA (cfDNA) as a minimally invasive cancer biomarker has great importance in cancer management. Guanylate binding protein 2 (GBP2) has been considered as a possible controlling factor in tumor development. GBP2 gene expression and its promoter methylation status in both plasma cfDNA and tumor tissues of ductal carcinoma breast cancer patients were analyzed using SYBR green comparative Real-Time RT-PCR and, Methyl-specific PCR techniques, respectively in order to find a possible cancer-related marker. The results revealed that GBP2 gene expression and promoter methylation were inversely associated. GBP2 was down-regulated in tumors with emphasis on triple negative status, nodal involvement and higher cancer stages (p<0.0001). GBP2 promoter methylation on both cfDNA and tumor tissues were positively correlated and was detected in about 88% of breast cancer patients mostly in (Lymph node positive) LN+ and higher stages. Data provided shreds of evidence that GBP2 promoter methylation in circulating DNA may be considered as a possible effective non-invasive molecular marker in poor prognostic breast cancer patients with the evidence of its relation to disease stage and lymph node metastasis. However further studies need to evaluate the involvement of GBP2 promoter methylation in progression-free survival or overall survival of the patients.
format Online
Article
Text
id pubmed-7783727
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Sociedade Brasileira de Genética
record_format MEDLINE/PubMed
spelling pubmed-77837272021-01-14 Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer Rahvar, Farzaneh Salimi, Mahdieh Mozdarani, Hossein Genet Mol Biol Human and Medical Genetics Blood methylated cell-free DNA (cfDNA) as a minimally invasive cancer biomarker has great importance in cancer management. Guanylate binding protein 2 (GBP2) has been considered as a possible controlling factor in tumor development. GBP2 gene expression and its promoter methylation status in both plasma cfDNA and tumor tissues of ductal carcinoma breast cancer patients were analyzed using SYBR green comparative Real-Time RT-PCR and, Methyl-specific PCR techniques, respectively in order to find a possible cancer-related marker. The results revealed that GBP2 gene expression and promoter methylation were inversely associated. GBP2 was down-regulated in tumors with emphasis on triple negative status, nodal involvement and higher cancer stages (p<0.0001). GBP2 promoter methylation on both cfDNA and tumor tissues were positively correlated and was detected in about 88% of breast cancer patients mostly in (Lymph node positive) LN+ and higher stages. Data provided shreds of evidence that GBP2 promoter methylation in circulating DNA may be considered as a possible effective non-invasive molecular marker in poor prognostic breast cancer patients with the evidence of its relation to disease stage and lymph node metastasis. However further studies need to evaluate the involvement of GBP2 promoter methylation in progression-free survival or overall survival of the patients. Sociedade Brasileira de Genética 2020-11-17 /pmc/articles/PMC7783727/ /pubmed/33211060 http://dx.doi.org/10.1590/1678-4685-GMB-2019-0230 Text en https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License
spellingShingle Human and Medical Genetics
Rahvar, Farzaneh
Salimi, Mahdieh
Mozdarani, Hossein
Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer
title Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer
title_full Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer
title_fullStr Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer
title_full_unstemmed Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer
title_short Plasma GBP2 promoter methylation is associated with advanced stages in breast cancer
title_sort plasma gbp2 promoter methylation is associated with advanced stages in breast cancer
topic Human and Medical Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783727/
https://www.ncbi.nlm.nih.gov/pubmed/33211060
http://dx.doi.org/10.1590/1678-4685-GMB-2019-0230
work_keys_str_mv AT rahvarfarzaneh plasmagbp2promotermethylationisassociatedwithadvancedstagesinbreastcancer
AT salimimahdieh plasmagbp2promotermethylationisassociatedwithadvancedstagesinbreastcancer
AT mozdaranihossein plasmagbp2promotermethylationisassociatedwithadvancedstagesinbreastcancer